It is worth noting that TPP‐LND@Lip nanoparticles developed by us solved the problems of PD‐L1 up‐regulation and tumor hypoxia at the same time, and showed better radiosensitization compared with PD‐L1 antibodies. This evidence concerns the gene CD274 and neoplasm.